8 years ago

Vaccitech Secures $27.1M Series A to Advance Universal Flu Vaccine

  • Oxford University spinout Vaccitech, a biotech company developing a universal flu vaccine, has raised $27.1M in Series A funding

  • The round was co-led by GV, Sequoia China, and Oxford Sciences Innovation, with participation from Neptune Ventures

  • The funding will be used to expand the company's business, develop its lab structure, and push its influenza and prostate cancer programs through Phase II clinical trials.

      • ProblemHealthcare

      "Developing a universal flu vaccine is notoriously difficult, and existing vaccines only provide protection against a limited number of flu strains. This means that people can still get sick even if they've been vaccinated."

      Solution

      "Vaccitech has developed a proprietary platform that induces strong cellular immune responses, leading to the development of a universal flu vaccine that can protect against a wide range of flu strains. This would significantly reduce the risk of flu outbreaks and provide long-lasting immunity."

      Covered on